每周股票复盘：麦澜德（688273）上半年营收增5.62%，净利降11.96%

Core Viewpoint - The company, 麦澜德, reported a decline in net profit for the first half of 2025 despite a revenue increase, primarily due to the disposal of a subsidiary's bad assets [2][3][7]. Financial Performance - For the first half of 2025, the company achieved a revenue of 241 million yuan, representing a year-on-year growth of 5.62% [2][3][7]. - The net profit attributable to shareholders was 63.92 million yuan, showing a year-on-year decrease of 11.96% [2][3][7]. Business Segments - The reproductive rehabilitation and anti-aging product lines were the main contributors to revenue growth, with a 42.45% increase in income from these segments, amounting to 79.84 million yuan [4][7]. - The company focuses on non-invasive brain-computer interface technology, with existing technical accumulations in upper limb and hand robotics, non-invasive neural regulation, and multi-modal physiological signal collection [4]. Strategic Initiatives - The company is developing emotional interaction products based on a national key research and development project, with plans to conduct clinical pre-experiments within the year [4]. - The overseas business primarily focuses on pelvic floor products, targeting Southeast Asia, with efforts to enhance promotion through exhibitions and academic exchanges [5]. Corporate Governance - The company plans to hold a second extraordinary general meeting in 2025 to discuss three proposals, including the reappointment of an auditing firm and the cancellation of the supervisory board [6].